Uses and complications of mitomycin C in ophthalmology

Expert Opinion on Drug Safety

Volumn 6, Issue 1, 2007, Pages 27-32

  Mearza, Ali A ^a   Aslanides, Ioannis M ^a  

^a Emmetropia Mediterranean Eye Institute   (Greece)

Author keywords

Conjunctival neoplasia; Corneal haze; Glaucoma; Hypotony; Mitomycin C; Pterygium; Refractive surgery; Scleral necrosis; Trabeculectomy

Indexed keywords

CORTICOSTEROID; FLUOROURACIL; MITOMYCIN C;

ASTIGMATISM; CANCER RISK; CATARACT; CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; ENDOTHELIAL DYSFUNCTION; EYE CANCER; EYE DISEASE; EYE TOXICITY; FOLLOW UP; GLAUCOMA; HIGH MYOPIA; HUMAN; INTRAOCULAR HYPOTENSION; IRITIS; KERATOMILEUSIS; KERATOPATHY; OPHTHALMOLOGY; PHOTOPHOBIA; PHOTOREFRACTIVE KERATECTOMY; PTERYGIUM; PUNCTATE KERATITIS; RECURRENCE RISK; REVIEW; RISK REDUCTION; SCLERA DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; STENOSIS; TRABECULECTOMY; TREATMENT CONTRAINDICATION; VISUAL ACUITY; WOUND HEALING IMPAIRMENT;

EYE DISEASES; HUMANS; MITOMYCIN; OPHTHALMOLOGY;

EID: 33846420643     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.1.27     Document Type: Review

References (65)

1. GILLMAN AG, RALL TW, NIES AS, TAYLOR P: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Ed. Pergamon Press, New York, USA (1990):1247-1248.
2. ERLICHMAN C, KERR IG: Antineoplastic drugs. In: Principles of Medical Pharmacology, 5th ed. Kalan TH, Roschlau WHE (Eds), Decker (Philadelphia) and Mosby (St Louis), USA (1989):604-614.
3. KUNIMOTO N, MORI S: Studies on pterygium. Part IV. A treatment of the pterygium by mitomycin-C instillation. Nippon Ganka Gakkai Zasshi. (1963) 67:601-607.
4. HAYASAKA S, NODA S, YAMAMOTO Y et al.: Postoperative instillation of low-dose mitomycin-C in the treatment of primary pterygium. Am. J. Ophthalmol. (1988) 106:715-718.
5. DONNENFELD ED, PERRY HD, FROMER S et al.: Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. Ophthalmology (2003) 110:1012-1026.
6. PALMER SS: Mitomycin C as adjunct chemotherapy with trabeculectomy. Ophthalmology (1994) 101:759-762.
7. JOHNSTONE MA, SHINGLETON BJ, CRANDALL AS et al.: Glaucoma surgery treatment patterns of ASCRS members - 2000 survey. J. Cataract Refract. Surg. (2001) 27:1864-1871.
8. MIETZ H, JACOBI PC, KRIEGLSTEIN GK: Intraoperative episcleral versus postoperative topical application of mitomycin-C for trabeculectomies. Ophthalmology (2002) 109:1343-1349.
9. HEIGLE TJ, STULTING RD, PALAY DA: Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin-C. Am. J. Ophthalmol. (1997) 124:397-399.
10. WILSON MW, HUNGERFORD JL, GEORGE SM et al.: Topical mitomycin-C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am. J. Ophthalmol. (1997) 124:303-311.
11. AKPEK EK, HASIRIPI H, CHRISTEN WG et al.: A randomised trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology (2000) 107:263-269.
12. MAJMUDAR PA, BRENART R, EPSTEIN RJ: Topical mitoycin-C for massive subepithelial fibrosis following radial keratotomy. Cornea (1998) 17:242-243.
13. MAJMUDAR PA, FORSTOT SL, DENNIS RF et al.: Topical mitomycin-C for subepithelial fibrosis following corneal refractive surgery. Ophthalmology (2000) 107:89-94.
14. VIGO L, SCANDOLA E, CARONES F: Scraping and mitomycin C to treat haze and regression after photrefractive keratectomy for myopia. J. Refract. Surg. (2003) 19:449-454.
15. ORAM O, GROSS RL, WILHELMUS KR et al.: Necrotizing keratitis following trabeculectomy with mitomycin. Arch. Ophthalmol. (1995) 113:19-20.
16. DUNN JP, SEAMONE CD, OSTLER HB et al.: Development of scleral ulceration and calcification after pterygium excision and mitomycin therapy. Am. J. Ophthalmol. (1991) 112:343-344.
17. RUBINFELD RS, PFISTER RR, STEIN RM et al.: Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology (1992) 99:1647-1654.
18. JAROS PA, DELUISE VP: Pingueculae and pterygia. Surv. Ophthalmol. (1988) 33:41-49.
19. HIRST LW, SEBBAN A, CHANT D: Pterygium recurrence time. Ophthalmology (1994) 101:755-758.
20. MANNING CA, KLOESS PM, DIAZ MD, YEE RW: Intraoperative mitomycin in primary pterygium excision. A prospective, randomised trial. Opthalmology (1997) 104:844-848.
21. MASTROPASQUA L, CARPINETO P, CIANCAGLINI M, GALLENGA PE: Topical mitomycin C for pterygium surgery. Ophthalmology (1997) 104:563-564.
22. POTERIO MB, ALVES MR, CARDILLO JA, JOSE NK: An improved surgical technique for pterygium excision with intra-operative application of mitomycin C. Ophthalmic Surg. Lasers (1998) 29:685-687.
23. SALOMAO DR, MATHERS WD, SUTPHIN JE et al.: Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy. Ophthalmology (1999) 106:1756-1760.
24. SOLOMON A, KAISERMAN I, RAISKUP FD et al.: Long-term effects of mitomycin C in pterygium surgery on scleral thickness and the conjunctival epithelium. Opthalmology (2004) 111:1522-1527.
25. LAM DS, WONG AK, FAN DS et al.: Intraoperative mitomycin C to prevent recurrence of pterygium after excision - a 30-month follow up study. Ophthalmology (1998) 105:901-905.
26. SANDERS SP, CANTOR LB, DOBLER AA et al.: Mitomycin C in higher risk trabeculectomy: a prospective comparison of 0.2 - 0.4-mg/cc doses. J. Glaucoma (1999) 8:193-198.
27. KOOK MS, KIM HB, LEE SU: Short-term effect of mitomycin-C augmented trabeculectomy on axial length and corneal astigmatism. J. Cataract Refract. Surg. (2001) 21:518-523.
28. MIETZ H, KRIEGLSTEIN GK: Three-year follow-up of trabeculectomies performed with different concentrations of mitomycin-C. Ophthalmic Surg. Lasers (1998) 29:628-634.
29. BINDLISH R, CONDON GP, SCHLOSSER JD et al.: Efficacy and safety of mitomycin-C in primary trabeculectomy - five year follow up. Ophthalmology (2002) 109:1336-1342.
30. BUSBEE BG, RECHHIA FM, KAISER R et al.: Bleb associated endophthalmitis. Ophthalmology (2004) 111:1495-1503.
31. HARA T, ARAIE M, SHIRATO S et al.: Conditions for balance between lower normal pressure control and hypotony in mitomycin trabeculectomy. Graefes Arch. Clin. Exp. Ophthalmol. (1998) 236:420-425.
32. ROBIN AL, RAMAKRISHNAN R, KRISHNADAS R et al.: A long-term dose-response study of mitomycin in glaucoma filtration surgery. Arch. Ophthalmol. (1997) 115:969-974.
33. BRANCATO R, TAVOLA A, CARONES F et al.: Excimer laser photorefractive keratectomy for myopia: results in 1165 eyes. Refract. Corneal Surg. (1993) 9:95-104.
34. SALZ JJ, MAGUEN E, NESBURN AB et al: A two year experience with excimer laser photorefractive keratectomy for myopia. Ophthalmology (1993) 100:873-882.
35. GARTRY DS, KERR MUIR MG, MARSHALL J: Excimer laser photorefractive keratectomy. 18-month follow up. Ophthalmology (1992) 99:1209-1219.
36. PALLIKARIS IG, PAPATZANAKI ME, STATHI EZ et al: Laser in situ keratomileusis. Lasers Surg. Med. (1990) 10:463-468.
37. LEE YC, HU FR, WANG IJ: Quality of vision after laser in situ keratomilieusis. Influence of dioptric correction and pupil size on visual function. J. Cataract Refract. Surg. (2003) 29:769-777.
38. HERSH PS, BRINT SF, MALONEY RK et al.: Photrefractive keratectomy versus laser in situ keratomileusis for moderate to high myopia: a randomised prospective study. Ophthalmology (1998) 105:1512-1522.
39. MCCARTY CA, ALDRED GF, TAYLOR HR: Comparison of results of excimer laser correction of all degrees of myopia ar 12 months postoperatively; the Melbourne Excimer Laser Group. Am. J. Ophthalmol. (1996) 121:372-383.
40. WACHTLIN J, LAUGENBECK K, SCHRUNDER S et al.: Immunohistology of corneal wound healing after photorefractive keratectomy and laser in situ keratomilieusis. J. Refract. Surg. (1999) 15:451-458.
41. XU H, LIU S, XIA X et al.: Mitomycin C reduces haze formation in rabbits after excimer laser photorefractive keratectomy. J. Cataract Refract. Surg. (2001) 17:342-349.
42. CARONES F, VIGO L, SCANDOLA E et al.: Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy. J. Cataract Refract. Surg. (2002) 28:2088-2095.
43. GAMBATO C, G HIRLANDO A, MORETTO E et al.: Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology (2005) 112:208-219.
44. MORALES AJ, ZADOK D, MORA-RETANA R et al.: Intraoperative mitomycin and corneal endothelium after photrefractive keratectomy. Am. J. Ophthalmol. (2006) 142:400-404.
45. CHANG SW: Early corneal oedema following topical application of mitomycin-C. J. Cataract Refract. Surg. (2004) 30:1742-1750.
46. TORRES RM, MERAYO-LLOVES J, DAYA SM et al.: Presence of mitomycin-C in the anterior chamber after photorefractive keratectomy. J. Cataract Refract. Surg. (2006) 32:67-71.
47. MCDERMOTT ML, WANG J, SHIN DH: Mitomycin and the human corneal endothelium. Arch. Ophthalmol. (1994) 112:533-537.
48. DONNENFELD ED, PERRY HD, WALLERSTEIN A et al.: Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology (1999) 106:72-79.
49. ADENIS JP, SOMMER U, ROBERT PY: Use of mitomycin C (MMC) for dacryocystorhinostomy interventions. J. Fr. Ophthalmol. (2005) 28:443-446.
50. KHONG JJ, MUECKE J: Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br. J. Ophthalmol. (2006) 90:807-809.
51. MURPHY WM, SOLOWAY MS, FINEBAUM PJ: Pathological changes with topical chemotherapy for superficial bladder cancer. J. Urol. (1981) 126:461-464.
52. KOSHIKAWA T, LEYH H, SCHENCK U: Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer. Diagn. Cytopathol. (1989) 5:117-121.
53. GOYAL JL, RAO VA, SRINIVASAN R, AGRAWAL K: Oculocutaneous manifestations in xeroderma pigmentosa. Br. J. Ophthalmol. (1994) 78:295-297.
54. SAUDER G, JONAS JB: Limbal stem cell deficiency after subconjunctival mitomycin C injection for trabeculectomy. Am. J. Ophthalmol (2006) 141:1129-1130.
55. MIETZ H, ROTERS S, KRIEGLSTEIN GK: Bullous keratopathy as a complication of trabeculectomy with mitomycin C. Graefes Arch. Clin. Exp. Ophthalmol. (2005) 243:1284-1287.
56. KENYON KR, WAGONER MD, HETTINGER ME: Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology (1985) 92:1461-1470.
57. BOBERG-ANS J, VEDEL KESSING S: Pterygium excision with limbal autograft. Eur. J. Implant Refract. Surg. (1995) 7:66-69.
58. MUTLU FM, SOBACI G, TATAR T, YILDIRIUM E: A comparative study of recurrent pterygium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap. Ophthalmology (1999) 106:817-821.
59. CHEN PP, ARIYASU RG, KAZA V, LABREE LD, MCDONNELL PJ: A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am. J. Ophthalmol. (1995) 120:151-160.
60. SINGH K, MEHTA K, SHAIKH NM et al.: Trabeculectomy with intraoperative Mitomycin C versus 5-flourouracil - prospective randomised clinical trial. Ophthalmology (2000) 107:2305-2309.
61. WUDUNN D, CANTOR LB, PALANCA-CAPISTRANO AM et al.: A prospective randomized trial comparing intraoperative 5-fluorouracil versus mitomycin C in primary trabeculectomy. Am. J. Ophthalmol. (2002) 134:521-528.
62. KATZ GJ, HIGGINBOTHAM EJ, LICHTER PR et al.: Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology (1995) 102:1263-1269.
63. AKARSU C, ONOL M, HASANREISOGLU B: Postoperative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow up. Clin. Exp. Ophthalmol. (2003) 31:199-205.
64. O'BRART DP, LOHMANN CP, KLONOS G et al.: The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy. A prospective, randomised, observer-masked study. Ophthalmology (1994) 101:1565-1574.
65. GARTRY DS, KERR MUIR MG, LOHMANN CP, MARSHALL J: The effect of topical corticosteroids on refractive outcome and corneal haze after photorefractive keratectomy: a prospective, randomised, double-blind trial. Arch. Ophthalmol. (1992) 110:944-952. Prospective randomised, double-masked study.